These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 9816072

  • 1. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
    Miller GJ, Stapleton GE, Hedlund TE, Moffat KA.
    Clin Cancer Res; 1995 Sep; 1(9):997-1003. PubMed ID: 9816072
    [Abstract] [Full Text] [Related]

  • 2. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
    Skowronski RJ, Peehl DM, Feldman D.
    Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
    [Abstract] [Full Text] [Related]

  • 3. Clonal differences in expression of 25-hydroxyvitamin D(3)-1alpha-hydroxylase, of 25-hydroxyvitamin D(3)-24-hydroxylase, and of the vitamin D receptor in human colon carcinoma cells: effects of epidermal growth factor and 1alpha,25-dihydroxyvitamin D(3).
    Bareis P, Kállay E, Bischof MG, Bises G, Hofer H, Pötzi C, Manhardt T, Bland R, Cross HS.
    Exp Cell Res; 2002 Jun 10; 276(2):320-7. PubMed ID: 12027461
    [Abstract] [Full Text] [Related]

  • 4. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
    Hedlund TE, Moffatt KA, Miller GJ.
    Endocrinology; 1996 May 10; 137(5):1554-61. PubMed ID: 8612485
    [Abstract] [Full Text] [Related]

  • 5. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
    Masuda S, Byford V, Arabian A, Sakai Y, Demay MB, St-Arnaud R, Jones G.
    Endocrinology; 2005 Feb 10; 146(2):825-34. PubMed ID: 15498883
    [Abstract] [Full Text] [Related]

  • 6. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
    Ly LH, Zhao XY, Holloway L, Feldman D.
    Endocrinology; 1999 May 10; 140(5):2071-6. PubMed ID: 10218956
    [Abstract] [Full Text] [Related]

  • 7. Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase.
    Roy S, Martel J, Tenenhouse HS.
    J Bone Miner Res; 1995 Dec 10; 10(12):1951-9. PubMed ID: 8619376
    [Abstract] [Full Text] [Related]

  • 8. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF.
    Clin Cancer Res; 2000 Mar 10; 6(3):901-8. PubMed ID: 10741714
    [Abstract] [Full Text] [Related]

  • 9. Consequences of vitamin D receptor regulation for the 1,25-dihydroxyvitamin D3-induced 24-hydroxylase activity in osteoblast-like cells: initiation of the C24-oxidation pathway.
    Staal A, van den Bemd GJ, Birkenhäger JC, Pols HA, van Leeuwen JP.
    Bone; 1997 Mar 10; 20(3):237-43. PubMed ID: 9071474
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. 1,25-Dihydroxyvitamin D3 induces 25-hydroxyvitamin D3-24-hydroxylase in a cultured monkey kidney cell line (LLC-MK2) apparently deficient in the high affinity receptor for the hormone.
    Chandler JS, Chandler SK, Pike JW, Haussler MR.
    J Biol Chem; 1984 Feb 25; 259(4):2214-22. PubMed ID: 6321462
    [Abstract] [Full Text] [Related]

  • 12. Regulation of messenger ribonucleic acid expression of 1 alpha,25-dihydroxyvitamin D3-24-hydroxylase in rat osteoblasts.
    Nishimura A, Shinki T, Jin CH, Ohyama Y, Noshiro M, Okuda K, Suda T.
    Endocrinology; 1994 Apr 25; 134(4):1794-9. PubMed ID: 8137744
    [Abstract] [Full Text] [Related]

  • 13. The role of Vitamin D3 metabolism in prostate cancer.
    Lou YR, Qiao S, Talonpoika R, Syvälä H, Tuohimaa P.
    J Steroid Biochem Mol Biol; 2004 Nov 25; 92(4):317-25. PubMed ID: 15663995
    [Abstract] [Full Text] [Related]

  • 14. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
    Zhao XY, Peehl DM, Navone NM, Feldman D.
    Endocrinology; 2000 Jul 25; 141(7):2548-56. PubMed ID: 10875257
    [Abstract] [Full Text] [Related]

  • 15. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
    Barreto AM, Schwartz GG, Woodruff R, Cramer SD.
    Cancer Epidemiol Biomarkers Prev; 2000 Mar 25; 9(3):265-70. PubMed ID: 10750664
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D.
    Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF, Chen TC.
    Anticancer Res; 2006 Mar 25; 26(4A):2567-72. PubMed ID: 16886665
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.